Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Maintenance in Ovarian Cancer
NCT00791778Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2008
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in ovarian epithelial cancer and primary peritoneal cancer (PPC) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Progression-free Survival at 32.5 months. Started Nov 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00791778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791778.